Partially Hydrolyzed Guar Gum (PHGG) for Amelioration of Chronic Obstructive Pulmonary Disease (COPD)

Fu Jen Catholic University Hospital

Status: Unknown

Conditions: Microbial Colonization; COPD; Respiratory Tract Disease

Treatments: Dietary Supplement: Partially Hydrolyzed Guar Gum (PHGG)

Study type: Interventional

Funder types: Other

Identifiers

NCT05126654

FJUH110120

Details and patient eligibility

About

Some components of the diet could promote the growth of certain bacterial strains present in the intestine, which are closely associated with benefits for host health. An intestinal commensal Parabacteroides goldsteinii (Pg) was highlighted to be significantly negatively associated with severity of COPD. Furthermore, the investigators identify the potential prebiotics (PHGG) which may enrich the abundance of P. goldsteinii and increase the probiotic effect of P. goldsteinii.

The investigators designed a randomized control study, which enroll adults diagnosed with COPD. Then the two groups will receive PHGG or not. Stool samples will be collected. The ameliorative efficacy will be evaluated by questionnaire and lung function test. Intestinal microbiota and metabolome will be analyzed and the correlation with lung function indices will be further investigated.

Full description

It is well known that some components of the diet could promote the growth of certain bacterial strains present in the intestine, which are closely associated with benefits for host health. In the previous study, the investigators found that an intestinal commensal Parabacteroides goldsteinii (Pg) was highlighted to be significantly negatively associated with severity of COPD. Furthermore, the investigators identify the potential prebiotics (PHGG) which may enrich the abundance of P. goldsteinii and increase the probiotic effect of P. goldsteinii. However, the effect of PHGG supplement on compositional and functional properties of the human microbiota with COPD still remains unclear.

In this proposal, the investigators designed a randomized control study, which enroll adults diagnosed with COPD. The investigators will review their past medical records and related image and lung function test. Then the two groups will receive PHGG or not. Stool samples will be collected. The ameliorative efficacy will be evaluated by questionnaire and lung function test. Intestinal microbiota and metabolome will be analyzed and the correlation with lung function indices will be further investigated. In the future, it may be used to investigate and analyze the change of microbiota and metabolome, then develop possible treatment options of COPD.

Enrollment: 60 estimated patients

Sex: All

Ages: 40 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age of 40-85 years
• diagnosis of COPD made by pulmonologist
• provision of written informed consent

Exclusion criteria

• severe and unstable comorbidities or active malignancy
• COPD exacerbation within the 4 weeks prior
• cognitive impairment or a psychiatric disorder
• pregnancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 4 patient groups

COPD with PHGG

Experimental group

Description:

COPD patient PHGG 5g/day for 1 month

Treatment:

Dietary Supplement: Partially Hydrolyzed Guar Gum (PHGG)

COPD without PHGG

No Intervention group

Description:

COPD patient without PHGG 5g/day for 1 month

Healthy with PHGG

Active Comparator group

Description:

Healthy PHGG 5g/day for 1 month

Treatment:

Dietary Supplement: Partially Hydrolyzed Guar Gum (PHGG)

Healthy without PHGG

No Intervention group

Description:

Healthy without PHGG 5g/day for 1 month